Fremanezumab-A Humanized Monoclonal Anti-CGRP Antibody-Inhibits Thinly Myelinated (Aδ) But Not Unmyelinated (C) Meningeal Nociceptors.

@article{MeloCarrillo2017FremanezumabAHM,
  title={Fremanezumab-A Humanized Monoclonal Anti-CGRP Antibody-Inhibits Thinly Myelinated (Aδ) But Not Unmyelinated (C) Meningeal Nociceptors.},
  author={Agustin Melo-Carrillo and Andrew M Strassman and Rony-Reuven Nir and Aaron J Schain and Rodrigo Noseda and Jennifer Stratton and Rami Burstein},
  journal={The Journal of neuroscience : the official journal of the Society for Neuroscience},
  year={2017},
  volume={37 44},
  pages={10587-10596}
}
Calcitonin gene-related peptide (CGRP), the most abundant neuropeptide in primary afferent sensory neurons, is strongly implicated in the pathophysiology of migraine headache, but its role in migraine is still equivocal. As a new approach to migraine treatment, humanized anti-CGRP monoclonal antibodies (CGRP-mAbs) were developed to reduce the availability… CONTINUE READING